Novo Nordisk | NVO - Loan Capital


Novo Nordisk reported DKK14.02B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
ANI Pharmaceuticals USD 286M 5.84M Mar/2026
Aurora Cannabis CAD 33.2M 1.79M Dec/2025
Bausch Health Companies USD 19.9B 720M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Canopy Growth CAD 224.99M 1.34M Dec/2025
Drreddys Laboratories INR 129.19M 1.84M Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Merck USD 46.67B 77M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Novartis USD 37.45B 7.86B Mar/2026
Novo Nordisk DKK 119.17B 231M Mar/2026
Novo Nordisk DKK 14.02B 224.49M Sep/2025
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.62B 17.5M Mar/2026
Phibro Animal Health USD 597.68M 5.92M Mar/2026
Prestige Brands USD 1.01B 40.28M Mar/2026
Sanofi EUR 13.84B 1.88B Mar/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
Zoetis USD 9.04B 3M Mar/2026